FilingsTodayQuest Diagnostics
At a glance
Quest Diagnostics reported 2025 revenue of $11.04B, up 11.8% from $9.87B in 2024. Over 4 years since 2021 ($10.79B), that is growth of about 0.6% a year. Operating margin was 14.1%, down from 22.1% in 2021. 2025 was the highest revenue year in this period.
In the last 12 months 8 insiders reported 0 open-market purchases and 22 sales ($37.3M). 20 of the sales were made under pre-arranged 10b5-1 plans. The largest was a sale of $10.6M by CEO and President J. E. Davis on Nov 28, 2025.
Quest Diagnostics filed 11 current reports (Form 8-K) in the last 12 months, most often for results of operations (5), other events (2), officer or director change (2) and shareholder vote results (1). The latest officer or director change was reported on Oct 6, 2026. It reported a material agreement or a completed acquisition or disposal 1 time.
2 of the 20 investors tracked here held Quest Diagnostics at the last quarter end, worth $10.6M combined. It is the largest weight for National Pension Service (Korea) (0% of its portfolio), followed by Bridgewater Associates (0%). Added: Bridgewater Associates. Reduced: National Pension Service (Korea).
Annual results
| Year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Net income | $2B | $946M | $854M | $871M | $992M |
| Diluted EPS | $15.55 | $7.97 | $7.49 | $7.69 | $8.75 |
Fiscal year ends Dec 31 · incorporated in DE
Tracked investors holding (13F)
Weight is the share of each investor's portfolio, as of the quarter end.
Current reports (8-K, last 12 months)
Insider open-market trades (last 12 months)
Source: SEC EDGAR. How figures are combined